Longview Acquisition Corp. II (NYSE:LGV – Get Rating) and Sight Sciences (NASDAQ:SGHT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
Insider & Institutional Ownership
62.1% of Longview Acquisition Corp. II shares are held by institutional investors. Comparatively, 65.2% of Sight Sciences shares are held by institutional investors. 26.4% of Longview Acquisition Corp. II shares are held by insiders. Comparatively, 44.3% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Get Longview Acquisition Corp. II alerts:Analyst Ratings
This is a summary of current recommendations and price targets for Longview Acquisition Corp. II and Sight Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longview Acquisition Corp. II | 0 | 0 | 0 | 0 | N/A |
| Sight Sciences | 0 | 2 | 4 | 0 | 2.67 |
Earnings & Valuation
This table compares Longview Acquisition Corp. II and Sight Sciences' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longview Acquisition Corp. II | N/A | N/A | $7.40 million | N/A | N/A |
| Sight Sciences | $48.96 million | 11.73 | -$62.96 million | ($1.79) | -6.66 |
Longview Acquisition Corp. II has higher earnings, but lower revenue than Sight Sciences.
Volatility & Risk
Longview Acquisition Corp. II has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
Profitability
This table compares Longview Acquisition Corp. II and Sight Sciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longview Acquisition Corp. II | N/A | -65.52% | 3.65% |
| Sight Sciences | -130.24% | -42.18% | -33.95% |
Summary
Sight Sciences beats Longview Acquisition Corp. II on 7 of the 10 factors compared between the two stocks.
About Longview Acquisition Corp. II
(Get Rating)
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
About Sight Sciences
(Get Rating)
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for Longview Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longview Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.